poster

Healthcare Resource Utilization and Costs of Using Cariprazine as the First Versus Subsequent Adjunctive Therapy for Major Depressive Disorder

Adjunctive therapy with atypical antipsychotics is a treatment option for patients diagnosed with major depressive disorder and inadequate response to antidepressant monotherapy. This cla...

10/26/2023

Healthcare Resource Utilization Following 6 Months of Treatment With Olanzapine/Samidorphan: Real-World Assessment of Patients With Schizophrenia or Bipolar I Disorder

This retrospective analysis of administrative claims data compared healthcare resource utilization 6 months before and after initiating a combination of olanzapine and samidorphan (OLZ/SA...

10/26/2023

Huffing and Puffing with Olanzapine: Olanzapine-Induced Dyspnea

This case report demonstrates a relationship between Olanzapine and hyperventilation. Increased minute ventilation on the ventilator while on olanzapine therapy, lack of other causes of i...

10/26/2023

Impact of Adjunctive Cariprazine on Quality of Life in Major Depressive Disorder: A Post Hoc Analysis

Patients with major depressive disorder often have reduced quality of life. A previous phase 3 trial showed cariprazine adjunctive to antidepressant therapy reduces depressive symptoms in...

10/26/2023

Impact of AXS-05 (Dextromethorphan-Bupropion) on Patient-Reported Insomnia Symptoms: Results from the GEMINI Trial

In GEMINI, AXS-05, an oral NMDA receptor antagonist approved for MDD, showed significantly higher response rates (defined as 50% reduction in QIDS insomnia score) starting at Week 3 throu...

10/26/2023

Impact of Fremanezumab Treatment on Disability Outcomes in Patients With Migraine and Major Depressive Disorder: Results of the UNITE Study

Depression is a prevalent comorbidity associated with migraine, and the bidirectional relationship between the two disorders can negatively impact quality of life (QoL). During the 12-wee...

10/26/2023

Estimation of Healthcare Cost Savings with Zuranolone in Major Depressive Disorder using Health-related Quality of Life to Predict Healthcare Costs

The Medical Expenditure Panel Survey was used to identify adults with major depressive disorder, to predict the association between health-related quality of life scores and annual health...

10/26/2023

Evaluating the opioid epidemic in a large county jail: Who is most at risk?

This poster aims to explore the comorbidity of mental health conditions (MDD, BPD, GAD, and Schizophrenia) with opioid use disorder in people incarcerated at a large urban jail.

10/26/2023

Evaluation of Mania and Hypomania in Late-Phase Clinical Trials of Lumateperone in the Treatment of Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder

This analysis evaluated mania and hypomania across 2 pooled, 6-week, placebo-controlled monotherapy studies; a 6-month open-label extension (OLE) monotherapy study; and a 6-week, placebo-...

10/26/2023

Exposure–Response Analysis to Compare Changes in the Clinical Endpoints for Tardive Dyskinesia and Chorea in Huntington Disease Following Once-Daily and Twice-Daily Tablet Formulations of Deutetrabenazine

Exposure-Response models using predicted exposure of deutetrabenazine’s active metabolites following BID and QD formulation administration, and therapeutic responses in the phase 3 TD and...

10/26/2023

Tracks

MDD Insights

Schizophrenia Insights

Major Depressive Disorder

General Psychiatry

ADHD

About

Celebrating 35 years of empowering the highest standard in mental healthcare, Psych Congress serves as a unique, integrated forum to connect members of the entire mental health team—bringing together psychiatrists, nurse practitioners, physician assistants, psychologists, primary care physicians, and other mental health professionals for 4 days of practical education to improve patient care.

December 9 ⁠–⁠ December 11

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

May 28 ⁠–⁠ May 31

See Full Calendar

poster

Tracks

About

Specialties

Events

Year Round Education

HMP Global Products